Metformin causes nitric oxide-mediated dilatation in a shorter time than insulin in the iliac artery of the anesthetized pig

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 2, 2012, Pages 182-187

  O'Hora, Theres Ruane ^a   Markos, Farouk ^a   Wiernsperger, Nicolas F ^b   Noble, Mark I M ^c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b CarMeN   (France)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

anesthetized pig; arterial dilatation; conduit artery; hyperglycemia; iliac artery; insulin; metformin; nitric oxide

Indexed keywords

INSULIN; METFORMIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; HYPERINSULINEMIA; ILIAC ARTERY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SWINE; TREATMENT RESPONSE;

ANIMALS; ENDOTHELIUM, VASCULAR; FEMALE; HYPOGLYCEMIC AGENTS; ILIAC ARTERY; INSULIN; METFORMIN; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; SWINE; TIME FACTORS; VASODILATION;

EID: 84857049568     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31823b4b94     Document Type: Article

References (34)

1. Caro C, Fitz-Gerald J, Schroter R. Arterial wall shear and distribution of early atheroma in man. Nature. 1969;223:1159-1160.
2. Caro CG, FitzGerald JM, Schroter RC. Atheroma and arterial wall shear. Observation, correlation and proposal of a shear dependent mass transfer mechanism for atherogenesis. Proc R Soc Lond B Biol Sci. 1971;177: 109-159.
3. Caro C. Discovery of the role of wall shear in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:156-161.
4. Kelly R, Ruane-O'Hora T, Noble MIM, et al. Differential inhibition by hyperglycaemia of shear stress- but not acetylcholine-mediated dilatation in the iliac artery of the anaesthetised pig. J Physiol. 2006;573:133-145. (Pubitemid 43670863)
5. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84:9265-9269.
6. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res. 2009;32: 1103-1108.
7. Duncan E, Ezzat V, Kearney M. Insulin and endothelial function: physiological environment defines effect on atherosclerotic risk. Curr Diabetes Rev. 2006;2:51-61.
8. Green D, Cheetham C, Mavaddat L, et al. Effect of lower limb exercise on forearm vascular function: contribution of nitric oxide. Am J Physiol Heart Circ Physiol. 2002;283:H899-H907.
9. Cardillo C, Kilcoyne CM, Nambi SS, et al. Vasodilator response to systemic but not to local hyperinsulinemia in the human forearm. Hypertension. 1998;32:740-745. (Pubitemid 28480554)
10. Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation. 1999;1008:820-825. (Pubitemid 29398879)
11. Ruane O'Hora T, Markos F, Wainwright C, et al. The responses of the iliac artery to insulin: direct delayed nitric oxide-mediated dilatation. Br J Diabetes Vasc Dis. 2011;11:129-135.
12. Sirtori CR, Francheschini G, Gianfranceschi G, et al. Metformin improves peripheral vascular flow in nonhyperlipemic patients with arterial disease. J Cardiovasc Pharmacol. 1964;6:914-923.
13. Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27:1349-1357. (Pubitemid 38679982)
14. Mather JM, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37: 1344-1350.
15. Katakam PVG, Ujhelyi MR, Hoenig M, et al. Metformin improves vascular function in insulin-resistant rats. Hypertension. 2000;35: 108-112. (Pubitemid 30054245)
16. Matsumoto T, Noguchi E, Ishida K, et al. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol. 2008;295:H1165-H1176.
17. Davis BJ, Xie Z, Viollet B, et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55:496-505. (Pubitemid 43343281)
18. Hattori Y, Suzuki K, Hattori S, et al. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006;47:1183-1188. (Pubitemid 44289177)
19. Huang NL, Chiang SH, Hsueh CH, et al. Metformin inhibits TNF-alphainduced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol. 2009;134:169-175.
20. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. J Clin Invest. 1996;98:894-898.
21. Zeng G, Nystrom FH, Ravichandran V, et al. Roles for insulin receptor, P13-kinase, and Akt in insulin-signalling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000; 101:1539-1545. (Pubitemid 30180890)
22. Muniyappa R, Montagnani M, Koh KK, et al. Cardiovascular actions of insulin. Endocr Rev. 2007;28:463-491. (Pubitemid 47236334)
23. Walker AB, Savage MW, Dores J, et al. Insulin-induced attenuation of noradrenaline-mediated vasoconstriction in resistance arteries from Wistar rats is nitric oxide dependent. Clin Sci. 1997;92:147-152. (Pubitemid 27075716)
24. Han SZ, Ouchi O, Karaki H, et al. Inhibitory effects of insulin on cytosolic Ca2+ level and contraction in rat aorta. Endothelium-dependent and -independent mechanisms. Circ Res. 1995;77:673-678.
25. Stubbs PJ, Alaghband-Zadeh J, Laycock JF, et al. The prognostic significance of an index of insulin resistance on admission in non-diabetic patients with acute coronary syndromes. Heart. 1999;82:443-447. (Pubitemid 29475203)
26. Stubbs P, Seed M, Lane D, et al. Lipoprotein (a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J. 1998;19:1355-1364. (Pubitemid 28427137)
27. Stubbs PJ, Al-Obaidi MK, Conroy RM, et al. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation. 2000;102:605-610. (Pubitemid 30640658)
28. Wiernsperger NF. Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther. 2000;2:259-272. (Pubitemid 30412827)
29. Wiernsperger NF. 50 years later: is metformin a vascular drug with antidiabetic properties? Br J Diabetes Vasc Dis. 2007;7:204-210. (Pubitemid 350055237)
30. Bouskela E, Wiernsperger N. Microcirculation: a unique target for metformin. In: Mithieux G, Wiernsperger N, eds. Metformin: Mechanistic Insights Towards New Applications. Kerala, India: Transworld Research Network; 2008:163-186.
31. Sachidanandam K, Hutchinson JR, Elgebaly MM, et al. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol. 2009;296: R952-R959.
32. Boyle JG, Salt IP, McKay GA. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target. Diabet Med. 2010;27:1097-1106.
33. Ouvang J, ParakhiaRA, Ochs RS. Metformin activates AMP-kinase through inhibition of AMP deaminase. J Biol Chem. 2011;286:1-11.
34. Pasarín M, Abraldes JG, Rodríguez-Vilarrupla A, et al. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol. 2011;55:1095-1102.